HIGHLIGHTS
- who: Ziqiang Han from the China The Ohio State University have published the research: Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study, in the Journal: (JOURNAL) of October/18,/2021
- what: The research of tumor immune checkpoint inhibitors mainly focuses on three molecules: cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) and its ligand PD-L1, such as camrelizumab, sintilimab, pembrolizumab, atezolizumab, tislelizumab, nivolumab, ipilimumab. If the deposition effect of lipiodol is good, TACE may . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.